Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...
Q1 2021 revenue of $14.3 million, Adjusted EBITDA of $6.7 million and cash from operations of $7.2 million, up $0.4 million, $0.6 million and $1.8 million, respectively, from Q1 2020 Vascepa...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2021 financial results on Thursday, May 6, 2021. The Company will hold a conference call that same...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and...